Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162119 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL4769824 | 0.93 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAHTTASAH1L3MBTL1 | |
| SCHEMBL21070867 | 0.89 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL21069431 | 0.88 | EPHX2 (0.61) | SMN1; SMN2LMNAHTTEPHX2L3MBTL1 | |
| SCHEMBL21071040 | 0.88 | EPHX2 (0.61) | SMN1; SMN2LMNAHTTEPHX2L3MBTL1 | |
| SCHEMBL29025356 | 0.87 | EPHX2 (0.57) | SMN1; SMN2LMNAHTTEPHX2L3MBTL1 | |
| SCHEMBL20819322 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAHTTASAH1EPHX2 | |
| SCHEMBL30316999 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAHTTNAAAL3MBTL1 | |
| SCHEMBL23043307 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAHTTASAH1 | |
| SCHEMBL30159248 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAHTTNAAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097678-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2023-03-30 | — | — | US | disclosed |
| EP-4110776-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2023-01-04 | — | — | EP | disclosed |
| CN-115151538-A | Macrocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-10-04 | — | — | CN | disclosed |
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | SMN1; SMN2 974/4885LMNA 2664/4885HTT 2877/4885 |
| US-20230097678-A1 | NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1S, C1R, F12 | SMN1; SMN2 3435/4885LMNA 1022/4885HTT 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.